Syndax Pharmaceuticals, Inc.
SNDX
$20.17
-$0.24-1.18%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -5.62% | 49.83% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -5.62% | 49.83% | |||
| Cost of Revenue | -96.76% | 39.34% | |||
| Gross Profit | 593.15% | -0.88% | |||
| SG&A Expenses | -25.32% | 12.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -24.77% | 27.47% | |||
| Operating Income | 45.67% | -9.62% | |||
| Income Before Tax | 37.63% | -12.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 37.26% | -12.02% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 37.26% | -12.02% | |||
| EBIT | 45.67% | -9.62% | |||
| EBITDA | 45.67% | -9.61% | |||
| EPS Basic | 37.90% | -11.09% | |||
| Normalized Basic EPS | 38.26% | -11.73% | |||
| EPS Diluted | 37.90% | -11.09% | |||
| Normalized Diluted EPS | 38.26% | -11.73% | |||
| Average Basic Shares Outstanding | 1.03% | 0.85% | |||
| Average Diluted Shares Outstanding | 1.03% | 0.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||